The PAM50 test, designed to determine a risk of recurrence (ROR) score for patients with Breast cancer, adds significant prognostic information to clinical decision making and might be superior to other risk assays, findings from two recent studies indicate.

The assay is based on the PAM50 gene signature, which measures expression profiles for 50 genes and classifies tumors into four intrinsic subtypes

• luminal A
• luminal B
• HER2-enriched
• basal-like

An algorithm is then used to combine the gene signature, intrinsic subtype, tumor size, and proliferation score.

Incoming Links #

Related Medical Scholarly Articles (MedicalScholarlyArticle 0) #

• Comprehensive molecular portraits of human breast tumours

Suggested Pages #

• 0.025 RNA-Seq Blog
• 0.025 Exome sequencing
• 0.025 2015
• 0.025 2014
• 0.025 2017
• 0.025 2016
• 0.025 2013
• 0.025 2012
• 0.025 May 10
• 0.025 May 13
• More suggestions...